Skip to Content

Nizatidine Pregnancy and Breastfeeding Warnings

Nizatidine is also known as: Axid, Axid AR, Axid Oral Solution, Axid Pulvules

Medically reviewed on Jul 12, 2018

Nizatidine Pregnancy Warnings

Nizatidine has been assigned to pregnancy category B by the FDA. Animal studies have revealed no evidence of impaired fertility or harm to the fetus. There are no controlled data in human pregnancy. Nizatidine should only be given during pregnancy when benefit outweighs risk.

See references

Nizatidine Breastfeeding Warnings

Nizatidine is excreted into human milk in small amounts. In one study, less than 0.1% of the maternal dose was eliminated in milk over 12 hours. The manufacturer recommends that due to the growth depression seen in pups reared by lactating rats while receiving nizatidine, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

The secretion of nizatidine into breast milk was studied in three lactating women. Following administration of nizatidine 150 mg, either one time or every 12 hours for five doses, an average of 96 mcg of nizatidine was secreted into milk over 12 hours. This amount represents 0.064% of the maternal dose.

See references

References for pregnancy information

  1. "Product Information. Axid (nizatidine)." Lilly, Eli and Company, Indianapolis, IN.

References for breastfeeding information

  1. Obermeyer BD, Bergstrom RF, Callaghan JT, Knadler MP, Golichowski A, Rubin A "Secretion of nizatidine into human breast milk after single and multiple doses." Clin Pharmacol Ther 47 (1990): 724-30
  2. "Product Information. Axid (nizatidine)." Lilly, Eli and Company, Indianapolis, IN.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.